Source - RNS
RNS Number : 1151I
Alliance Pharma PLC
14 June 2017
 

For immediate release

14 June 2017

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Application for admission

 

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that following the exercise of employee share options, application has been made by Alliance for a further 571,000 ordinary shares of 1p each in the Company ("Ordinary Shares") to be admitted to trading on AIM.

 

It is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 20 June 2017.

 

After admission, Alliance will have 473,962,681 Ordinary Shares in issue.

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0) 1249 466966

John Dawson, Chief Executive

Andrew Franklin, Chief Financial Officer

 

Rob Bellhouse, Company Secretary

 

www.alliancepharma.co.uk

 

 

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Sophie Cowles / Jane Glover

 

 

 

Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

 

Corporate Broking: James Black / Toby Adcock

 

 

Notes to editors:

 

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ALSLLFEERLISLID